Klempa I
Klinik für Allgemein- und Gefässchirurgie, Zentralkrankenhaus St.-Jürgen-Strasse Bremen.
Chirurg. 1999 Oct;70(10):1089-101. doi: 10.1007/s001040050870.
Nearly all patients with chronic renal failure exhibit some degree of secondary hyperparathyroidism (sHPT), defined as parathyroid hyperplasia and elevated serum parathyroid hormone (PTH) levels. Despite improvements in the medical management of patients with sHPT continue to develop progressive bone disease manifested by osteitis fibrosa cystica, soft tissue calcification and myopathy, pruritus, bone and joint pain and calciphylaxis may accompany the bone disorder. When medical therapy fails, parathyroidectomy becomes necessary. This is not sufficiently explained by the failure to administer calcitriol to control serum phosphate and calcium concentration or to deliver sufficient dialysis. The continuous increase of the proportion of patients exhibiting severe uncontrolled HPT with increasing time of dialysis points to a more basic underlying biological problem; an even higher proportion of patients shows also nodular, rather than diffuse hyperplasia. It was commonly believed that after restoration of normal renal function with successful transplantation, the hyperplastic parathyroid glands would involute and return to normal function state. After renal transplantation some patients continue to have a HPT. This disease entity is recognized and termed as tertiary Hyperparathyroidism (tHPT). After establishing a diagnosis of hyperparathyroid bone disease, in patients with sHPT and tHPT a parathyroidectomy (PTX) frequently becomes necessary to decrease the mass of the hyperplastic parathyroid tissue. The surgical procedure remains controversial. Some surgeons prefer subtotal PTX, others prefer total PTX with autotransplantation of a small amount of tissue to the arm, because the transplanted tissue can be removed in the event of a recurrent HPT. Successful surgical intervention for sHPT and tHPT significantly reduces preoperative symptoms and leeds to restoration of bone disease and therefore supports PTX for patients with s and tHPT. In our experience total PTX with autograft has proven to be a satisfactory procedure. Subtotal PTX is also an effective procedure and the choice of operative technique should be left to the surgeon.
几乎所有慢性肾衰竭患者都存在一定程度的继发性甲状旁腺功能亢进(sHPT),其定义为甲状旁腺增生和血清甲状旁腺激素(PTH)水平升高。尽管sHPT患者的药物治疗有所改善,但仍会继续发展为进行性骨病,表现为纤维囊性骨炎、软组织钙化和肌病,骨病可能伴有瘙痒、骨和关节疼痛以及钙化防御。当药物治疗失败时,甲状旁腺切除术就变得必要。未能使用骨化三醇控制血清磷酸盐和钙浓度或进行充分透析并不能充分解释这一情况。随着透析时间的增加,表现为严重 uncontrolled HPT 的患者比例持续上升,这表明存在更基本的潜在生物学问题;更高比例的患者还表现为结节性而非弥漫性增生。人们普遍认为,肾移植成功恢复正常肾功能后,增生的甲状旁腺会 involute 并恢复到正常功能状态。肾移植后,一些患者仍患有 HPT。这种疾病实体被认识并称为三发性甲状旁腺功能亢进(tHPT)。在确诊甲状旁腺骨病后,对于 sHPT 和 tHPT 患者,通常需要进行甲状旁腺切除术(PTX)以减少增生的甲状旁腺组织量。手术方式仍存在争议。一些外科医生倾向于次全 PTX,另一些则倾向于全 PTX 并将少量组织自体移植到手臂,因为如果 HPT 复发,可以切除移植的组织。对 sHPT 和 tHPT 进行成功的手术干预可显著减轻术前症状并使骨病恢复,因此支持对 sHPT 和 tHPT 患者进行 PTX。根据我们的经验,自体移植的全 PTX 已被证明是一种令人满意的手术方式。次全 PTX 也是一种有效的手术方式,手术技术的选择应留给外科医生。